Ascendis Pharma to raise capital with convertible notes
Biotech firm Ascendis Pharma intends to offer convertible notes for a sum of USD 500m.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Danish biotech firm Ascendis Pharma, which is listed in the US, wants to raise USD 500m by offering convertible notes, the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma reports promising phase III data
For subscribers
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers
